Cargando…

Editorial: Antibody Therapeutics for the Treatment of Filoviral Infection

Detalles Bibliográficos
Autores principales:	Murin, Charles D., Gunn, Bronwyn M., Parren, Paul W. H. I., Kobinger, Gary P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894432/ https://www.ncbi.nlm.nih.gov/pubmed/35251051 http://dx.doi.org/10.3389/fimmu.2022.859919

Ejemplares similares

Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging
por: Darling, Tamarand Lee, et al.
Publicado: (2017)

Filoviral Immune Evasion Mechanisms
por: Ramanan, Parameshwaran, et al.
Publicado: (2011)

Infection Control During Filoviral Hemorrhagic Fever Outbreaks
por: Vanessa, N Raabe, et al.
Publicado: (2012)

Detection of biomarkers for filoviral infection with a silicon photonic resonator platform
por: Meserve, Krista, et al.
Publicado: (2022)

Emerging Filoviral Disease in Uganda: Proposed Explanations and Research Directions
por: Polonsky, Jonathan A., et al.
Publicado: (2014)

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection
por: Nelson, Elizabeth A., et al.
Publicado: (2017)

The role of antigen-presenting cells in filoviral hemorrhagic fever: Gaps in current knowledge
por: Martinez, Osvaldo, et al.
Publicado: (2012)

Establishment of Fruit Bat Cells (Rousettus aegyptiacus) as a Model System for the Investigation of Filoviral Infection
por: Krähling, Verena, et al.
Publicado: (2010)

Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage
por: Fenimore, Paul W., et al.
Publicado: (2012)

Editorial: Effector functions of therapeutic antibodies
por: Boross, Peter, et al.
Publicado: (2023)

Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity
por: Murin, Charles D.
Publicado: (2020)

Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity
por: Akpovwa, Hephzibah
Publicado: (2016)

Editorial: Antibody Fc Engineering: Towards Better Therapeutics
por: Lei, Cheng, et al.
Publicado: (2018)

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development
por: Murin, Charles D., et al.
Publicado: (2022)

Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg?
por: Kremer, Leonor, et al.
Publicado: (2018)

Editorial: Contemporary challenges in diagnosis and treatment of predominantly antibody deficiency
por: Ameratunga, Rohan, et al.
Publicado: (2022)

Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry
por: Parren, Paul W.H.I., et al.
Publicado: (2013)

Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more
por: Parren, Paul W. H. I., et al.
Publicado: (2017)

Editorial: Immunity to Cytomegalovirus Infections: Challenges and Therapeutic Opportunities
por: Alonso-Arias, Rebeca, et al.
Publicado: (2022)

Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography
por: Fox, Julie M., et al.
Publicado: (2023)

Editorial: Advances in T Cell Therapeutic Vaccines for HIV
por: Macatangay, Bernard J. C., et al.
Publicado: (2022)

Editorial: Understanding and Engineering Antibody-Superantigen Interactions
por: Gan, Samuel Ken-En, et al.
Publicado: (2022)

Novel human antibody therapeutics: The age of the Umabs
por: Ruuls, Sigrid R, et al.
Publicado: (2008)

Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells
por: van der Wulp, Willemijn, et al.
Publicado: (2023)

Editorial: Natural Antibodies in Health and Disease
por: Hernandez, Ana Maria, et al.
Publicado: (2017)

Editorial: The Complexity of Primary Antibody Deficiencies
por: Quinti, Isabella, et al.
Publicado: (2021)

Editorial: Immunogenicity of Proteins Used as Therapeutics
por: Sauna, Zuben E., et al.
Publicado: (2020)

Editorial: Epigenetics of B Cells and Antibody Responses
por: Zan, Hong, et al.
Publicado: (2016)

Editorial: Host immune response and regulation to parasitic infections: therapeutic approaches and defence strategies
por: Siddiqui, Arif Jamal, et al.
Publicado: (2023)

Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
por: Wagh, Kshitij, et al.
Publicado: (2021)

The antiviral activity of antibodies in vitro and in vivo
por: Parren, Paul W.H.I., et al.
Publicado: (2001)

Editorial: A hill of needs: Non-HLA antibodies and transplantation
por: Otten, H.G., et al.
Publicado: (2022)

Editorial: Immunology of HPV Infection and Vaccination: Progress and Challenges
por: Licciardi, Paul V., et al.
Publicado: (2021)

Editorial: Lessons on T-Cells and Immune-Targeting Therapeutics in Coeliac Disease
por: Hardy, Melinda Y., et al.
Publicado: (2021)

Therapeutic Antibodies against Intracellular Tumor Antigens
por: Trenevska, Iva, et al.
Publicado: (2017)

Editorial: Macrophage immunity and metabolism in cancer: Novel diagnostic and therapeutic strategies
por: Leavenworth, Jianmei W., et al.
Publicado: (2022)

Editorial: Regulation of Inflammation, Its Resolution and Therapeutic Targeting
por: Uguccioni, Mariagrazia, et al.
Publicado: (2017)

Editorial: Advances in therapeutic strategies of inborn errors of immunity
por: Pilania, Rakesh Kumar, et al.
Publicado: (2023)

Editorial: TNFRSF agonists: mode of action and therapeutic opportunities
por: Obermajer, Nataša, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8rfu4i7dq4r3vlad0kb57o5mmk